BioNTech SE - American Depositary Shares (NQ:BNTX)

96.90 +0.05 (+0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

September 08, 2025

From Pfizer Inc.

Via Business Wire

Why BioNTech Stock Crushed the Market Today ↗

September 05, 2025

The company might be close to commercializing its most advanced pipeline program.

Via The Motley Fool

Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday ↗

September 05, 2025

Via Benzinga

Why Did BioNTech Stock Surge 10% Pre-Market Today? ↗

September 05, 2025

Via Stocktwits

Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population ↗

August 27, 2025

Via Stocktwits

Breaking Down BioNTech: 12 Analysts Share Their Views ↗

August 05, 2025

Via Benzinga

Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? ↗

September 05, 2025

It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.

Via Investor's Business Daily

BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb ↗

September 05, 2025

The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.

Via Investor's Business Daily

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data ↗

September 05, 2025

BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.

Via Benzinga

Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works ↗

September 01, 2025

Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest.

Via Benzinga

BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push ↗

August 04, 2025

Via Stocktwits

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

A Look Ahead: BioNTech's Earnings Forecast ↗

August 01, 2025

Via Benzinga

Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? ↗

August 31, 2025

Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.

Via Benzinga

RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines ↗

August 27, 2025

FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.

Via Benzinga

RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles. ↗

August 27, 2025

Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday.

Via Investor's Business Daily

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

August 27, 2025

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

August 27, 2025

From BioNTech SE

Via GlobeNewswire

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' ↗

August 25, 2025

The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic.

Via Benzinga

Topics Government

3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer ↗

August 13, 2025

This big pharma company's juicy dividend is looking even more attractive.

Via The Motley Fool

Topics Earnings

CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency ↗

August 12, 2025

CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy.

Via Benzinga

Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk ↗

August 11, 2025

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.

Via Benzinga

These Analysts Revise Their Forecasts On BioNTech After Q2 Results ↗

August 05, 2025

Via Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth ↗

August 04, 2025

BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.

Via Benzinga

BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected ↗

August 04, 2025

BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances.

Via Chartmill

Topics Earnings

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

August 04, 2025

From BioNTech SE

Via GlobeNewswire

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Moderna's Key Patent Win Overshadowed By Gloomy Outlook ↗

August 01, 2025

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.

Via Benzinga

Topics Intellectual Property

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion ↗

July 31, 2025

Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings.

Via Benzinga

Where Will Pfizer (PFE) Be in 5 Years? ↗

July 31, 2025

The big drugmaker should be even bigger over the next five years despite facing a patent cliff.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.